Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...

Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth ...

Novo Nordisk (NVO) shares stumble after the results of the drugmaker's weight loss drug trial showed that patients using the drug dropped only around 15% of their weight, compared to the 25% that ...

Mounting competition in the sector and rising obesity have led the pharmaceutical company to start selling the drug directly ...

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...

Discover the latest experimental obesity drug from Novo Nordisk, achieving 15.7% weight loss after 68 weeks, which fell short of the company's expectations.

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Despite the results, the company is still in a strong position to continue leading the weight loss space. Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or ...